Latest News about NTLA
Recent news which mentions NTLA
From Benzinga
Here's the Holy Grail of Gene Editing
April 02, 2021
From Motley Fool
Investing in CRISPR Stocks: Ultimate Genetic Editing Guide
March 31, 2021
From InvestorPlace
From Motley Fool
From InvestorPlace
Walter Isaacson, Author of 'The Code Breaker,' On Dr. Jennifer Doudna And CRISPR Gene Editing
March 10, 2021
From Motley Fool
82 Biggest Movers From Yesterday
March 10, 2021
From Benzinga
Biotech stocks are a buy — especially these 18 picks
March 09, 2021
From MarketWatch
From Benzinga
Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript
February 25, 2021
Tickers
NTLA
From Motley Fool
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
February 25, 2021
From Benzinga
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
February 20, 2021
From Benzinga
Will Editas Medicine's CEO Change Help or Hurt?
February 20, 2021
From Motley Fool
Where Will Editas Medicine Be in 5 Years?
February 17, 2021
From Motley Fool
3 Top Healthcare Stocks to Buy in February
February 12, 2021
From Motley Fool
Tickers
NTLA
From InvestorPlace
Of Politics and Stock Prices
January 17, 2021
From Motley Fool
7 CRISPR Stocks for the Future of Medicine
January 15, 2021
From InvestorPlace
Stocks That Hit 52-Week Highs On Friday
January 15, 2021
From Benzinga
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
January 08, 2021
From Benzinga
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today
December 29, 2020
From Motley Fool
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
December 29, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Monday
December 28, 2020
From Benzinga
Benzinga's Top Upgrades, Downgrades For December 22, 2020
December 22, 2020
From Benzinga
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
December 22, 2020
From Benzinga
82 Biggest Movers From Yesterday
December 22, 2020
From Benzinga
55 Stocks Moving In Monday's Mid-Day Session
December 21, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Monday
December 21, 2020
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.